ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.3211C>T (p.His1071Tyr) (rs80358564)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000572282 SCV000661193 likely benign Hereditary cancer-predisposing syndrome 2017-10-20 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: In silico models in agreement (benign),Other strong data supporting benign classification
Breast Cancer Information Core (BIC) (BRCA2) RCV000113148 SCV000146191 uncertain significance Breast-ovarian cancer, familial 2 2004-02-20 no assertion criteria provided clinical testing
Color RCV000572282 SCV000903952 uncertain significance Hereditary cancer-predisposing syndrome 2018-05-31 criteria provided, single submitter clinical testing
Counsyl RCV000113148 SCV000489593 uncertain significance Breast-ovarian cancer, familial 2 2016-10-27 criteria provided, single submitter clinical testing
GeneDx RCV000212225 SCV000210310 uncertain significance not provided 2014-10-20 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.3211C>T at the cDNA level, p.His1071Tyr (H1071Y) at the protein level, and results in the change of a Histidine to a Tyrosine (CAT>TAT). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. This variant has been reported in the Breast Cancer Information Core (BIC) database as having unknown clinical importance. BRCA2 His1071Tyr was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Histidine and Tyrosine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. BRCA2 His1071Tyr occurs at a position that is highly variable across species and is located in the RAD51 binding domain (Roy 2012). In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available information, it is unclear whether BRCA2 His1071Tyr is pathogenic or benign. We consider it to be a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.